Skip to main content
Equibles
IART logo

IART · Integra Lifesciences Holdings Corp

Track IART — free

Use IART with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$16.72 +0.28 (+1.70%) At close · Sep 4
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.30B
Shares
77.77M

IART metrics

78 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$16.72
Market cap
$1.30B

Price action

19 metrics
Price change (1W)
-1.0%
Price change (30D)
-2.1%
Price change (3M)
-1.6%
Price change (6M)
+71.8%
Price change (YTD)
+34.6%
Price change (1Y)
+6.8%
Trailing year
Price change (5Y)
-78.0%
52-week high
$19.85
52-week low
$8.90
Change from 52-week high
-15.8%
Change from 52-week low
+87.9%
Annualized volatility
61.1%
Beta
2.0
RSI (14D)
44.2
Price vs SMA 50
-6.1%
Price vs SMA 200
+21.3%
Avg volume (3M)
857,473
Relative volume
0.8
Average dollar volume
$15.28M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
77.77M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.1×
reciprocal yield 95.1%
EV / EBITDA
—
EV / EBIT
26.4×
reciprocal yield 3.8%
P / sales
0.8×
reciprocal yield 126.7%
P / book
1.2
reciprocal yield 80.2%
FCF yield
2.0%
TTM · current market cap
Buyback yield
0.0%
P / FCF
50.4
reciprocal yield 2.0%
P / operating cash flow
15.2
reciprocal yield 6.6%
Earnings yield
-0.6%

Historical valuation

8 metrics
P / E historical average (3Y)
35.6×
reciprocal yield 2.8%
P / E historical average (5Y)
48.7×
reciprocal yield 2.1%
EV / revenue historical average (3Y)
1.3×
reciprocal yield 76.6%
EV / revenue historical average (5Y)
2.2×
reciprocal yield 45.1%
EV / EBIT historical average (3Y)
59.8×
reciprocal yield 1.7%
EV / EBIT historical average (5Y)
41.6×
reciprocal yield 2.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
—
Operating margin
4.0%
Trailing 12 months
Net margin
-0.4%
Gross profit (TTM)
$851.03M
Operating profit (TTM)
$65.56M
Net income (TTM)
−$7.24M
Trailing 12 months
Diluted EPS (TTM)
$-0.10
FCF margin
1.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+0.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.65B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.9%
Year over year · more shares
Revenue CAGR (3Y)
+1.6%
Revenue CAGR (5Y)
+3.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-0.7%
Return on assets
-0.2%
Debt / equity
0.7
Current ratio
3.6
EBITDA (TTM)
$170.98M
Free cash flow (TTM)
$25.80M
Quick ratio
2.1
Interest coverage
0.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$433.10M
Latest balance sheet
Cash & equivalents
$214.41M
Total assets
$3.56B
Total debt
$707.19M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$85.33M
Capital expenditures (TTM)
$59.52M
R&D (TTM)
$95.00M
SG&A (TTM)
$688.98M
Stock compensation (TTM)
$22.43M
R&D / revenue
5.8%
Stock compensation / revenue
1.4%

Ownership (13F)

3 metrics
13F filers
213
13F filer change QoQ
+11
Institutional ownership
94.3%

Short interest

3 metrics
Short interest
8.7%
Latest settlement · 10.0 days to cover
Days to cover
10.0d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 917520 CUSIP 457985208 13F (30d) 137 filings 137 filers Visit website Investor relations